Ubs Group Ag Adverum Biotechnologies, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$0.75 - $1.26 $11 - $18
15 Added 1.88%
815 $0
Q3 2023

Nov 09, 2023
SELL
$1.5 - $2.33 $8,235 - $12,791
-5,490 Reduced 87.28%
800 $1,000
Q2 2023

Aug 11, 2023
SELL
$0.68 - $1.59 $5,908 - $13,815
-8,689 Reduced 58.01%
6,290 $10,000
Q1 2023

May 12, 2023
BUY
$0.62 - $0.85 $8,790 - $12,052
14,179 Added 1772.38%
14,979 $10,000
Q2 2022

Aug 10, 2022
SELL
$0.81 - $1.34 $202 - $335
-250 Reduced 23.81%
800 $1,000
Q1 2022

May 16, 2022
SELL
$1.23 - $1.95 $2.62 Million - $4.16 Million
-2,131,591 Reduced 99.95%
1,050 $1,000
Q4 2021

Feb 14, 2022
SELL
$1.74 - $2.4 $1.76 Million - $2.43 Million
-1,011,028 Reduced 32.16%
2,132,641 $3.75 Million
Q3 2021

Nov 15, 2021
BUY
$2.08 - $3.6 $46,473 - $80,434
22,343 Added 0.72%
3,143,669 $6.82 Million
Q2 2021

Aug 13, 2021
SELL
$3.36 - $10.56 $588,211 - $1.85 Million
-175,063 Reduced 5.31%
3,121,326 $10.9 Million
Q1 2021

May 12, 2021
BUY
$9.26 - $14.36 $4.74 Million - $7.35 Million
511,527 Added 18.37%
3,296,389 $32.5 Million
Q4 2020

Feb 11, 2021
BUY
$9.84 - $14.26 $18.4 Million - $26.7 Million
1,873,450 Added 205.55%
2,784,862 $30.2 Million
Q3 2020

Nov 12, 2020
SELL
$10.3 - $21.64 $7.73 Million - $16.3 Million
-750,938 Reduced 45.17%
911,412 $9.39 Million
Q2 2020

Jul 31, 2020
SELL
$8.53 - $25.64 $6.92 Million - $20.8 Million
-811,578 Reduced 32.81%
1,662,350 $34.7 Million
Q1 2020

May 01, 2020
SELL
$7.98 - $16.32 $2.71 Million - $5.55 Million
-340,003 Reduced 12.08%
2,473,928 $24.2 Million
Q4 2019

Feb 14, 2020
BUY
$5.12 - $12.22 $2.73 Million - $6.52 Million
533,264 Added 23.38%
2,813,931 $32.4 Million
Q3 2019

Nov 14, 2019
SELL
$5.24 - $15.89 $4.5 Million - $13.6 Million
-857,872 Reduced 27.33%
2,280,667 $12.4 Million
Q2 2019

Aug 14, 2019
BUY
$5.1 - $11.89 $5.48 Million - $12.8 Million
1,074,535 Added 52.06%
3,138,539 $37.3 Million
Q1 2019

May 14, 2019
BUY
$3.03 - $6.02 $3.62 Million - $7.18 Million
1,193,116 Added 137.0%
2,064,004 $10.8 Million
Q4 2018

Feb 14, 2019
BUY
$2.87 - $5.92 $2.44 Million - $5.04 Million
851,066 Added 4293.54%
870,888 $2.74 Million
Q3 2018

Nov 14, 2018
BUY
$4.5 - $7.6 $26,320 - $44,452
5,849 Added 41.86%
19,822 $120,000
Q2 2018

Aug 14, 2018
BUY
$5.3 - $6.9 $60,420 - $78,660
11,400 Added 443.06%
13,973 $74,000
Q1 2018

May 15, 2018
BUY
$3.65 - $7.95 $9,391 - $20,455
2,573 New
2,573 $15,000
Q4 2017

Feb 14, 2018
SELL
$2.85 - $3.95 $5,095 - $7,062
-1,788 Closed
0 $0
Q3 2017

Nov 14, 2017
SELL
$2.45 - $3.65 $1,560 - $2,325
-637 Reduced 26.27%
1,788 $6,000
Q2 2017

Aug 14, 2017
BUY
N/A
817 Added 50.81%
2,425 $6,000
Q1 2017

Nov 14, 2017
BUY
N/A
1,608
1,608 $4,000

Others Institutions Holding ADVM

# of Institutions
3
Shares Held
524K
Call Options Held
0
Put Options Held
0
View Full List

About Adverum Biotechnologies, Inc.

ADVM Quotes by TradingView
  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email